Abstract
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of 18 months. Although alogliptin did not increase cardiovascular risk, the drug also did not significantly reduce it.
Type 2 diabetes is associated with both microvascular and macrovascular complications.
1
The risk of cardiovascular disease is two to four times as high in people with diabetes as in people without diabetes.
1
,
2
Improved glycemic control can reduce the risk of many microvascular complications of diabetes,
3
but studies have not shown a favorable effect of glycemic control in reducing macrovascular events in patients with type 2 diabetes.
4
,
5
Concerns regarding adverse cardiovascular outcomes with antidiabetic agents
6
,
7
prompted the Food and Drug Administration (FDA) to issue guidance in December 2008 that included specific requirements for cardiovascular safety assessment before and . . .